Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a cash and stock deal valued at about $39 billion. There are a couple of sound reasons for this deal, as we detail below.
Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a cash and stock deal valued at about $39 billion. There are a couple of sound reasons for this deal, as we detail below.
Share this Article
Comment on this Article
Recommended
Please to comment